3899 - Everolimus

Material & Volume
  • EDTA Blood, 1ml
Reference values
Age Sex Pregnant Range Unit
All No 3.0-10.0 therapeutic range
>15 toxic
μg/l
Clinical Information

Type of drug: Immunosuppressive
Metabolism: CYP3A4, P-gp(ABCB1)
Half life t½: 26-38h
Steady State: 1-2 weeks
TDM: highly recommended/ norm of treatment
Additional informations: Levels of >15µg/l should be avoided due to the higher likelihood of side effects. Beware of interactions with CYP3A4 and P-gp(ABCB1) inhibitors.

Everolimus, as gained from actinomycytes, blocks the antigens’ activated T-cell proliferation of the G1-phase into the S-phase of the cell cycle by means of its immune suppressive characteristics. The mechanism is based on the bonding of the active agent with the mTOR protein, which leads to the inhibition of the cytokinin mediated signal transduction: i.e. the inhibition of the activating of the S6 ribosome proteins and the formation complex of the p34cdc2-kinase with cyclin E. For this reason everolimus is primarily administered after heart- and kidney –transplantations, but also for the therapy of kidney carcinomas. Moreover, the active agent can decelerate growth in polycystic kidneys and enhance kidney function. Possible side effects are infections, anaemia and thrombocytopenia.

Index
Synonyms
Product names
Analyses groups
etc.
  • Certican®
Position / Price
Position: 1469.00
Price: CHF 135.00
+ Processing fee:
(per order and per day)
CHF 21.60
Method
  • LC-MS
Executing laboratory
labor team w ag
Blumeneggstrasse 55
9403 Goldach
Execution time
1 day
Contact
During opening-hours:
Outside opening-hours: